DEF 14A: Avenue Therapeutics Seeks Stockholder Approval for Director Elections, Auditor Ratification, and Incentive Plan Amendment

Avenue Therapeutics is holding its annual stockholder meeting on June 24, 2024, to vote on the election of directors, ratification of auditors, and an amendment to the company's incentive plan.

Summary

• Avenue Therapeutics is holding its Annual Meeting of Stockholders virtually on June 24, 2024, at 9:30 a.m. Eastern Time.
• Stockholders will vote to elect six directors for a one-year term, ratify the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2024, and approve an amendment to the 2015 Incentive Plan.
• The proposed amendment to the 2015 Plan includes increasing the number of authorized shares by 5,000,000, extending the plan's term to June 24, 2034, increasing the limit of shares that may be issued upon the exercise of incentive stock options by 5,000,000 shares, and increasing the annual share limit for awards to non-employee directors to 500,000.
• The record date for determining stockholders eligible to vote at the Annual Meeting was April 30, 2024.
• The Board of Directors recommends voting FOR the election of all director nominees, FOR the ratification of KPMG LLP, and FOR the approval of the amendment to the 2015 Plan.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposed amendment to the incentive plan suggests a positive outlook for the company's ability to attract and retain talent.

Positives

• The company is taking steps to ensure continued access to equity-based compensation for employees and directors by proposing an amendment to the 2015 Incentive Plan.
• The Board is recommending qualified candidates for election as directors.
• The company is seeking to ratify a qualified independent registered public accounting firm.

Risks

• If the proposed amendment to the 2015 Incentive Plan is not approved, the company may face challenges in attracting and retaining key personnel due to limited equity compensation options.
• Failure to ratify the appointment of KPMG LLP could necessitate a review of the company's selection process for its independent registered public accounting firm.

Future Outlook

The company is seeking stockholder approval for an amendment to its 2015 Incentive Plan to ensure it can continue to attract, retain, and incentivize employees and non-employee directors with equity-based compensation.

Management Comments

• The Board believes that it is in the best interest of the Company for stockholders to approve this proposal, to ensure that the Company retains the ability to use equity awards as a means of compensation.

Industry Context

The use of equity compensation is a common practice in the biopharmaceutical industry to align the interests of management and employees with those of stockholders, and to attract and retain talent.

Comparison to Industry Standards

• Many comparable biopharmaceutical companies utilize equity incentive plans to attract and retain talent.
• The specific terms of Avenue Therapeutics' 2015 Incentive Plan, including the number of shares authorized and the types of awards available, are generally consistent with industry standards for companies of similar size and stage of development.
• Companies like Mustang Bio, Inc. (Nasdaq: MBIO), Journey Medical Corporation (Nasdaq: DERM) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT), each of which are subsidiaries of Fortress, also utilize equity compensation plans.

Related Party Transactions

• Fortress entered into a Founders Agreement with the Company in February 2015, pursuant to which Fortress assigned to the Company all of its rights and interest under Fortresss license agreement with Revogenex Ireland Ltd. for IV tramadol (the License Agreement).
• Effective as of February 17, 2015, Fortress entered into a Management Services Agreement (the MSA) with the Company to provide services to the Company pursuant to the terms of the MSA.
• In November 2022, we completed a Share Contribution Agreement, dated May 11, 2022 (the Share Contribution Agreement) with Fortress to acquire the shares in Baergic Bio, Inc. (Baergic).
• On September 8, 2023, we entered into an unwritten agreement with Fortress and Dr. Lindsay A. Rosenwald, a director on the Board (Dr. Rosenwald and Fortress, together, the Private Placement Investors), pursuant to which we agreed to issue and sell 10,227 shares (the September 2023 Private Placement Shares) of our common stock (the September 2023 Private Placement).

Stakeholder Impact

• Approval of the proposals will impact stockholders through potential changes in the Board of Directors, the selection of the independent auditor, and the company's ability to attract and retain talent.
• Employees and non-employee directors may be impacted by the proposed amendment to the 2015 Incentive Plan, which could affect their compensation.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 24, 2024.
• The company will implement the approved proposals following the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, KPMG LLP, 2015 Incentive Plan, Stockholders, Amendment, Shares, Voting, Avenue Therapeutics